

Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD

Francisco Espinoza, Pierre Le Blay and Bernard Combe

ABSTRACT. Objective. To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD).

Methods. We conducted a retrospective cohort study in 499 patients with rheumatic diseases treated by IV abatacept (ABA), infliximab (IFX), or tocilizumab (TCZ).

Results. Rheumatoid arthritis (RA) was the most frequent diagnosis (72%). Fifty-two patients (10.4%) experienced at least 1 episode of neutropenia. No episodes of grade 4 neutropenia were documented. TCZ was more frequently related to neutropenia than ABA or IFX (18.6% vs 3.8% and 2.8%, respectively, $p < 0.001$). The following factors were identified as predictors of experiencing neutropenia with IV bDMARD: history of neutropenia with methotrexate (MTX; synthetic DMARD; OR 1.56, 95% CI 1.17–7.14), concomitant treatment by MTX (OR 1.21, 95% CI 1.01–2.64), and TCZ treatment (OR 2.72, 95% CI 1.53–9.05). Patients experiencing a TCZ-induced neutropenia did not show a higher risk of severe infections; however, this group had a shorter drug survival (9 mos vs 20 mos, $p < 0.02$) compared with TCZ patients without neutropenia.

Conclusion. Among 3 different classes of IV bDMARD, TCZ is associated with the higher risk of neutropenia. No increased frequency of infection episodes was documented in this group. (First Release April 15 2017; J Rheumatol 2017;44:844–9; doi:10.3899/jrheum.150457)

Key Indexing Terms:

ANTIRHEUMATIC AGENTS NEUTROPENIA TOCILIZUMAB INFECTION

Biologic disease-modifying antirheumatic drugs (bDMARD) have redefined the treatment of rheumatic diseases over the past decade. Despite their well-recognized safety, hematologic abnormalities, and in particular, neutropenia have been reported^{1,2}.

Neutropenia is here defined by a circulating absolute neutrophil count (ANC) inferior to $2 \times 10^9/l^3$. Besides dissimilar data collected in pre- and postmarketing trials, only a few studies have investigated bDMARD-induced neutropenia in real-world cohorts of patients with rheumatic diseases. Hastings, *et al*⁴ reported on a large cohort with 367

patients treated by tumor necrosis factor (TNF) inhibitors, and found that 18.8% patients had at least 1 episode of neutropenia during treatment. To our knowledge, no comparison between different classes of biologics has ever been made. Further, aspects such as predisposing factors, involvement of concomitant therapy by synthetic DMARD (sDMARD), and consequences of neutropenia remain unclear. Because the major serious event of biologics is infection, a serious concern is whether bDMARD-induced neutropenia could eventually increase this risk.

The aim of this report is to examine neutropenia in a cohort of patients treated with 3 different classes of intravenous (IV) bDMARD: a CTLA-4 antagonist, abatacept (ABA); a TNF- α inhibitor (TNFi), infliximab (IFX); and an interleukin (IL)-6 inhibitor, tocilizumab (TCZ). Incidence, risk factors, and effect of neutropenia on both risk of infection and drug survival were analyzed.

MATERIALS AND METHODS

Study population. A retrospective study was conducted of 499 patients treated with at least 1 of 3 IV bDMARD (ABA, IFX, or TCZ) from April 2009 to June 2014 at the Department of Rheumatology of Lapeyronie University Hospital (Montpellier, France). The start of followup was the first infusion of IV bDMARD, and the end of followup was last infusion by

From the Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier, Montpellier, France; Department of Rheumatology, School of Medicine, Universidad de los Andes, Santiago, Chile.

F. Espinoza, MD, Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier and Department of Rheumatology, School of Medicine, Universidad de los Andes; P. Le Blay, MD, Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier; B. Combe, MD, PhD, Department of Rheumatology, Lapeyronie University Hospital, University of Montpellier.

Address correspondence to Dr. F. Espinoza, Department of Rheumatology, School of Medicine, Universidad de los Andes, 12455, Avenida Alvaro del Portillo, Santiago, Chile. E-mail: fespinoza@uandes.cl

Accepted for publication February 10, 2017.

calendar date, lost to followup, or death. The analysis was performed only in the IV form because all the clinical and laboratory data were available owing to the rigorous followup made in each monthly or bimonthly visit patients made to receive their infusion. The study has received approval from the CHU of Montpellier ethics board (Comité de Protection des Personnes, CHU Montpellier, registered code 2014-A00824-43).

Data were collected from medical records. Demographic, clinical, and therapeutic features were recorded, including age, sex, type of rheumatic disease, disease duration, antibody status, history of neutropenia, baseline neutrophil counts, lowest observed ANC, white blood cell count, platelets blood count, and concomitant or prior use of medications including DMARD, corticosteroids, and IV or subcutaneous (SC) biologics.

“Drug survival” measures the length of time a patient continues to take a particular drug and encompasses factors such as drug effectiveness and side effects. To measure it, we consider the time between the onset and the last dose of the drug. “Drug failure” may be defined as either a lack of efficacy or patient intolerance to the treatment.

Rate of infection/severe infection was also recorded and expressed as 100 patient-years (PY). The criteria for defining a severe infection were (1) severe sepsis, (2) any infection requiring hospitalization or IV antibiotics, (3) any infection leading to need for oxygen or intubation, and (4) any of the following: pneumonia, pyelonephritis, deep tissue (invasive) infection, pseudomembranous colitis because of *Clostridium difficile*, meningitis, osteomyelitis, disseminated or complicated herpes zoster, and any infection that requires adjunctive surgical intervention.

To define neutropenia severity, common toxicity criteria³ grade was used as follows: grade 1, ≥ 1.5 and $< 2.0 \times 10^9/l$; grade 2, ≥ 1.0 and $< 1.5 \times 10^9/l$; grade 3, ≥ 0.5 and $< 1.0 \times 10^9/l$, and grade 4 $< 0.5 \times 10^9/l^4$. The ANC was obtained within 3 days prior to IV biologic dose.

Statistical analysis. Comparisons were performed using the chi-square test for qualitative variables, and the Student t test or the Wilcoxon test depending on variable distribution for quantitative variable. To compare a variable in the 3 groups, a 1-way ANOVA test was performed. P value and 95% CI were estimated. To determine predisposing factors of neutropenia, a multivariate logistic regression analysis was done. Patients were divided into 2 groups according to the presence or absence of neutropenia. Comparisons were made between these 2 groups and variables associated with a p value inferior to 0.05 were chosen in a stepwise selection process to perform the analysis. OR and 95% CI were estimated.

A Cox regression analysis was carried out to estimate the HR of neutropenia comparing the 3 groups of treatment. With the purpose of analyzing TCZ survival between patients with and without neutropenia, a Mantel-Cox test was used. The significance level was set at 5% for all tests. Statistical analysis was performed using STATA software version 13.0 (StataCorp LP).

RESULTS

Demographics. Characteristics of the 499 patients are summarized in Table 1. Mean age was 57 years. Women represented 83% of the sample. Rheumatoid arthritis (RA) was the more common diagnosis (72.3%), followed by axial spondyloarthritis (AS; 20.2%). Concomitant treatment by sDMARD was documented in 51.5% of the sample and in 61.7% of patients with RA. Oral corticosteroid treatment was used by 49.8% of subjects. Sixty-four patients (12.8%) received 2 of the 3 IV bDMARD and 34 patients (6.8%) received all 3 of them. There were 129 patients treated with ABA, 213 with IFX, and 221 with TCZ (Table 2).

Analysis of neutropenia. Details are summarized in Table 3. At least 1 episode of neutropenia was recorded in 10.4% (n = 52) of patients (ANC range 0.6 – $1.94 \times 10^9/l$) and 96%

Table 1. General characteristics of cohort.

Characteristics	Values
Patients, n	499
Age, yrs, mean (SD)	57.2 (29.3)
Male/female, %	17.1/82.9
Diagnosis, n (%)	
Rheumatoid arthritis	361 (72.3)
Axial spondyloarthritis	101 (20.2)
Psoriatic arthritis	30 (6)
JIA	7 (1.4)
Antibody status, %	
RA with RF- or ACPA-positive	63.7
ANA in cohort	6.3
Disease duration, yrs, mean (SD)	15.8 (11.2)
Prior no. biologics, IV or SC, mean (95% CI)	1.8 (1.6–2.3)
Concomitant therapy, overall/RA patients, n (%)	
Methotrexate	218 (43.7)/193 (53.4)
Other sDMARD	39 (7.8)/30 (8.8)
Corticosteroids	246 (49.4)/179 (49.5)

JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; ANA: antinuclear antibody; IV: intravenous; SC: subcutaneous; sDMARD: synthetic disease-modifying antirheumatic drug.

Table 2. Characteristics of patients according to IV bDMARD. Values are % unless otherwise specified.

Characteristics	Abatacept	Infliximab	Tocilizumab	p*
Patients, n (%)	129 (22.9)	213 (37.9)	221 (39.2)	
Total time taking drug, mos, mean (SD)	27.4 (21.3)	41.7 (33.3)	31.1 (22.3)	0.03
Diagnosis				
Rheumatoid arthritis	98.4	31.9	92.3	
Axial spondyloarthritis	—	51.7	—	
Psoriatic arthritis	—	13.6	—	
JIA	1.6	2.8	7.2	
Concomitant sDMARD**				
Methotrexate	59.6	44.6	66.8	< 0.001
Leflunomide	12.4	2.34	5.4	< 0.001
Corticosteroids	48.9	49.9	50.6	0.46

* p values are supplemented as appropriate. ** At baseline. IV: intravenous; DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; JIA: juvenile idiopathic arthritis; sDMARD: synthetic DMARD.

of them presented more than 5 episodes. Most subjects (90%) experienced a moderate neutropenia (grades 2 and 3). No episodes of grade 4 neutropenia were registered. The mean ANC before starting the drug was $3.2 \pm 1.4 \times 10^9/l$. Suspensions of IV bDMARD were noted in 5.6% of patients because ANC was under $1 \times 10^9/l$. Treatment was stopped in only 1 patient (Felty syndrome) because of a concomitant severe thrombocytopenia. In this particular case, neutropenia improved transiently after stopping treatment; however, neutropenia returned later with an sDMARD.

Except for 1 patient who had AS, all other cases occurred

Table 3. Neutropenia and related variables according to IV bDMARD analyzed. Values are n unless otherwise specified.

Variables	Abatacept	Infliximab	Tocilizumab	p*
Neutropenia, n (%)**	5 (3.8)	6 (2.8)	41 (18.6)	< 0.001
Grade 1	1	0	4	
Grade 2	4	3	33	
Grade 3		2	4	
Grade 4				
Time to first episode of neutropenia, weeks, mean (range)	9.3 (3–11.5)	13.2 (2.2–18)	15.2 (1–108)	0.65
History of neutropenia, n (%)	4 (75)	3 (50)	3 (7.3)	< 0.001
sDMARD	3 (MTX)	2 (MTX)	1 (MTX)	
Biologic drug		1 (ADA)	2 (1 ADA/1 ETN)	
Hematologic disorder	1 (Felty)			
Other cytopenias, n (%)	1 (20)	1 (16.6)	9 (21.9)	0.96
Thrombocytopenia		1	3 (2 with lymphopenia)	
Lymphopenia			6	
Pancytopenia	1			

* p values are supplemented as appropriate. ** This value refers to the lowest ANC registered. IV: intravenous; DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; sDMARD: synthetic DMARD; MTX: methotrexate; ADA: adalimumab; ETN: etanercept; ANC: absolute neutrophil count.

in patients with RA. Neutropenia was more frequent with TCZ therapy (18.6% vs 2.8% and 3.8% in IFX and ABA groups, respectively, $p < 0.001$).

The first episode of neutropenia generally occurred within the first 3 months of treatment (median 9.5 weeks, range 1–108 weeks), although with TCZ therapy it was possible to identify 4 patients (9.7%) who developed neutropenia after the first year of treatment. Most patients receiving ABA and IFX had a history of neutropenia, mainly while treated with methotrexate (MTX). By contrast, patients experiencing their first event while treated with TCZ represented 93% of the group.

We found other cytopenias associated to neutropenia. Thrombocytopenia, lymphopenia, and the association of both were observed. No difference between the treatment groups was found. With ABA, 1 case of pancytopenia was identified. This patient had Felty syndrome. In 2 patients (1 ABA, 1 IFX), a bone marrow biopsy was performed showing in both cases a normal trilineage differentiation.

All patients receiving both ABA and IFX continued treatment without adjustments in dose or infusion interval. The course of neutropenia with TCZ therapy is analyzed below.

Predisposing factors of neutropenia. A multivariate logistic regression was performed to identify independent variables associated with the occurrence of neutropenia. Predisposing factors to develop neutropenia with IV bDMARD were (1) history of neutropenia while treated with MTX (OR 1.56, 95% CI 1.17–7.14), (2) concomitant use of MTX (OR 1.21, 95% CI 1.01–2.64), and (3) TCZ therapy (OR 2.72, 95% CI 1.53–9.05). No correlations with disease duration, antibodies status, or sex were identified (Table 4).

Neutropenia associated to TCZ therapy. Patients receiving

TCZ treatment had a higher risk of experiencing an episode of neutropenia compared with other treatments (HR 2.55, 95% CI 1.09–5.33, $p = 0.029$). Forty-one patients (18.6%) presented at least 1 episode of neutropenia. In those patients, we observed an ANC mean reduction of 32% compared with the baseline. The magnitude of neutropenia was not associated to treatment response [American College of Rheumatology (ACR) 20, ACR50]. No differences were found between neutropenic and no neutropenic patients regarding mortality rate (0.9 vs 1.1, $p = 0.89$).

Neutropenia with TCZ seemed to be dose-dependent: an incidence of only 7.2% was found in patients who started TCZ at 6 mg/kg in comparison with 25.8% of patients who started at 8 mg/kg ($p < 0.001$; Figure 1A).

A reduction of TCZ dose was made in 98.3% of patients experiencing more than 3 episodes of neutropenia. With this strategy, an increase in ANC from 1474 ± 44.9 cel/mm³ to 2010 ± 95.9 cel/mm³ was achieved ($p < 0.001$; Figure 1B). A longterm dose of 6 mg/kg was maintained in 27.1% of patients, but in all other cases (72.9%) the dose was finally reduced to 4 mg/kg.

No cases of drug withdrawal were observed. Nonetheless, treatment failure occurred more frequently in the group of patients experiencing neutropenia (16.6% vs 9.4%, $p < 0.001$), leading to a shorter median drug survival in those patients (9 mos vs 20 mos, 95% CI 1.16–14.78, $p < 0.02$) compared with TCZ patients without neutropenia (Figure 2).

Rate of infection regarding neutropenia. No differences were noted between TCZ patients with and without neutropenia regarding the rate of infection (92,100 PY vs 88,100 PY, 95% CI –0.04 to 0.07, $p = 0.15$) or severe infections (12,100 PY vs 11,100 PY, 95% CI –0.02 to 0.003, $p = 0.13$).

Table 4. Predisposing factors of neutropenia. Values are % unless otherwise specified.

Variables	Univariate Analysis			Multivariate Analysis	
	Neutropenia, n = 52	Without Neutropenia, n = 447	p	OR	95% CI
Age, yrs, mean (SD)	60.3 (24.2)	56.5 (30.4)	0.27		
Female	75	83.8	0.11		
Rheumatoid arthritis	98	69.3	0.001	2.14	0.89–6.79
Disease duration, yrs, mean (SD)	16.3 (10.5)	15.4 (12.5)	0.61		
RF- or ACPA-positive	65.3	63.5	0.96		
Prior neutropenia receiving sDMARD therapy	11.5	1.7	0.015	1.56	1.17–7.14
Current treatment					
Concomitant MTX	57.7	42.1	0.03	1.21	1.01–2.64
Concomitant PRED	48.1	49.4	0.88		
0–5 mg/day	47.3	46.2	0.92		
5–15 mg/day	32.4	36.1	0.75		
> 15 mg/day	9.6	11.2	0.81		
Abatacept	9.6	27.7	0.004		
Infliximab	11.5	46.3	0.001		
Tocilizumab	78.8	40.2	0.001	2.72	1.53–9.05

RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; sDMARD: synthetic disease-modifying antirheumatic drug; MTX: methotrexate; PRED: prednisone.

For IFX, the rate of infection was 97,100 PY (95% CI 79.1–121.3) and for ABA, 76,100 PY (95% CI 54.7–98.3). In both treatments, a comparison between patients with or without neutropenia was not possible because of the lower incidence of neutropenia.

DISCUSSION

In our study, we have scrutinized the characteristics of neutropenia associated to IV bDMARD in a real-world cohort of 499 patients with inflammatory rheumatic diseases. No comparative studies between biologics with different molecular targets have been previously published, to our knowledge. TCZ, an IL-6 inhibitor, entails a higher frequency of neutropenia in comparison to ABA, a CTLA-4 antagonist, and IFX, a TNFi. TCZ-induced neutropenia remains moderate, without an increased risk of infection, but is associated to a higher rate of drug failure.

Ten percent of patients in our cohort presented at least 1 episode of neutropenia with dissimilar frequencies between each group of treatment. In ABA and IFX, very low frequencies of neutropenia were found. In both groups, previous history of neutropenia, mostly with MTX, was documented.

ABA phase III/IV studies did not report episodes of neutropenia^{5,6,7,8}. Regarding IFX, initial safety studies suggested no increase in the risk of leukopenia^{9,10}. Although in later observational studies, an elevated frequency of neutropenia was described^{11,12}. Rajakulendran, *et al*¹³ reported an incidence of 14.3% in patients with RA. Subsequently, in an expanded cohort of patients with RA, AS, and psoriatic arthritis, Hastings, *et al*⁴ found an incidence of

18.8% for all TNFi [IFX, adalimumab (ADA), and etanercept] and up to 25.4% with IFX. Pappas, *et al*¹⁴ found an incidence of neutropenia of 13.8% in ADA and of 10.6% with other TNFi. In the analysis of 1322 biologic-naïve patients with RA of the Corrona registry, no increased risk for developing neutropenia with TNFi was found because in about 8.7% of patients a neutropenic episode had already been documented before TNFi was initiated.

Data for neutropenia with TCZ incidence are divergent. In the Tocilizumab Safety and THE Prevention of Structural Joint Damage (LITHE) study¹⁵, a neutropenia frequency of 4.5% at 8 mg/kg was found; while De Benedetti, *et al*¹⁶ in a cohort of 112 patients with juvenile idiopathic arthritis (JIA) found an incidence as high as 57%. Several other studies, such as the TOWARD (Tocilizumab in cOmbination With traditional DMARD therapy)¹⁷, RADIATE (RheumAtoiD ArthrItis study in Anti-TNF failurEs)¹⁸, or AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy)¹⁹ trials, reported a frequency around 30%. The SUMMACTA [A Study to compare subcutaneous versus intravenous administration of RoActemra/Actemra (Tocilizumab) in participants with moderate to severe active rheumatoid arthritis] study²⁰ comparing the safety and efficacy of IV versus SC TCZ found an incidence of 26% on IV and 37% on SC form. A dose-dependent effect on neutropenia-onset had been already noted in the LITHE and OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequate ResponDers)²¹ studies, where the incidence of neutropenia at 8 mg/kg was almost twice that observed at 4 mg/kg. In addition, data from these trials confirm that grade 4 neutropenia (< 0.5 ANC × 10⁹/l) is extremely uncommon.




Figure 1. Incidence of neutropenia according to TCZ dose. (A) Comparison of neutropenia incidence between doses of 6 mg/kg versus 8 mg/kg. (B) Kinetic of ANC after a dose reduction. *** $p < 0.001$. TCZ: tocilizumab; ANC: absolute neutrophil count.




Figure 2. Median drug survival by a Kaplan-Meier analysis between TCZ patients with and without neutropenia. TCZ: tocilizumab.

A multivariate analysis was performed to elucidate independent risk factors associated to the appearance of neutropenia on IV bDMARD. History of neutropenia with MTX was supported by Hastings, *et al*⁴ as a predisposing factor. Interestingly, the analysis shows that concomitant use of sDMARD predisposes to develop neutropenia with biologics. In the univariate analysis, an association between RA and neutropenia was obtained. However, 2 of the 3 IV biologics are prescribed only for RA, therefore this association was not confirmed in the final model.

We considered the consequences of neutropenia, in particular regarding treatment with TCZ. Our study did not find an increased risk of infection among neutropenic patients receiving TCZ. De Benedetti, *et al*¹⁶ did not document an increased rate of infections either over 112 patients with JIA with higher incidence of neutropenia. The likelihood of infection is related probably to severity and duration of neutropenia episodes. In our cohort, as in the patients with JIA, neutropenia episodes were moderate. Further, TCZ-induced neutropenia seems to be explained by the margination of circulating neutrophils provoked by IL-6 inhibition²². In this sense, neither the ANC nor phagocytic neutrophil function are diminished. On the other hand, a shorter drug survival among TCZ patients experiencing neutropenia was observed. It is likely that drug failure was related to dose reduction made in patients with repetitive episodes of neutropenia.

An important strength of our study is the analysis of a real-world cohort of rheumatic patients treated by different IV bDMARD. However, our report also has some limitations. The retrospective design of our study limited the gathering of more accurate data regarding neutrophil kinetics. We cannot evaluate the approach to neutropenia events, in particular modifications of TCZ dose. Findings such as the involvement of concomitant sDMARD in neutropenia or shorter TCZ survival in neutropenic patients must be verified in prospective studies.

We believe that the data presented here permit a better perspective on the problem regarding frequency, severity, associated risk factors, and consequences. We report 3 major findings: (1) risk factors for developing neutropenia with IV bDMARD are history of neutropenia with MTX, concurrent treatment with sDMARD, and TCZ therapy; (2) neutropenia with TCZ is not associated to an increased risk of infections; and (3) TCZ-induced neutropenia is dose-dependent. Shorter TCZ drug survival could be associated to dose decrease strategy to improve ANC.

REFERENCES

- Bessisow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. *Aliment Pharmacol Ther* 2012;36:312-23.
- Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. *Ann Intern Med* 2003;139:W-W63.

3. US National Cancer Institute. Common toxicity criteria manual, version 2.0. Bethesda: NCI; 1999.
4. Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots RJ, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. *Arthritis Care Res* 2010;62:764-9.
5. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med* 2005;353:1114-23.
6. Schiff M, Keiserman M, Coddling C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis* 2008;67:1096-103.
7. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. *Ann Rheum Dis* 2009;68:1708-14.
8. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. *Ann Rheum Dis* 2011;70:1826-30.
9. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol* 2003;30:2563-71.
10. Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. *Drug Saf* 2002;25:173-97.
11. Montané E, Sallés M, Barriocanal A, Riera E, Costa J, Tena X. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. *Clin Rheumatol* 2007;26:1527-9.
12. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept [letter]. *Rheumatology* 2008;47:376-7.
13. Rajakulendran S, Gadsby K, Allen D, O'Reilly S, Deighton C. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis [letter]. *Ann Rheum Dis* 2006;65:1678-9.
14. Pappas DA, Shaw JW, Chang H, Cifaldi MA, Reed GW, Garg V, et al. Laboratory safety of adalimumab and other tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis [abstract]. *Ann Rheum Dis* 2014;73 Suppl 2:931.
15. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum* 2011;63:609-21.
16. De Benedetti F, Rubio-Pérez N, Salazar CD, Goodman S, Job-Deslandre C, Joos R, et al. A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis [abstract]. *Arthritis Rheumatol* 2014;66 Suppl 3:S67-8.
17. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* 2008;58:2968-80.
18. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008;67:1516-23.
19. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis* 2010;69:88-96.
20. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). *Ann Rheum Dis* 2014;73:69-74.
21. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;371:987-97.
22. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. *Rheumatology* 2014;53:1321-31.